Novel therapies in peripheral T-cell lymphomas

Curr Oncol Rep. 2008 Sep;10(5):404-11. doi: 10.1007/s11912-008-0062-3.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of disorders associated with a very poor prognosis. Historically, treatment protocols have been largely based on regimens used to treat aggressive B-cell lymphomas; unfortunately, the efficacy of these regimens has been suboptimal, with most patients experiencing relapse after initial therapy. An improved understanding of the molecular biology, pathogenesis, and progression of these disorders has led to the development of a variety of novel targeted agents that may improve outcomes in patients with PTCLs. The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in PTCLs.

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Aminopterin / administration & dosage
  • Aminopterin / analogs & derivatives
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Clinical Trials as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Diphtheria Toxin / administration & dosage
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Immunotherapy / methods*
  • Interleukin-2 / administration & dosage
  • Lymphoma, T-Cell, Peripheral / therapy*
  • Medical Oncology / methods
  • Prognosis
  • Recombinant Fusion Proteins / administration & dosage
  • Treatment Outcome

Substances

  • 10-propargyl-10-deazaaminopterin
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Diphtheria Toxin
  • Enzyme Inhibitors
  • Interleukin-2
  • Recombinant Fusion Proteins
  • Deoxycytidine
  • denileukin diftitox
  • Alemtuzumab
  • gemcitabine
  • zanolimumab
  • Aminopterin